Основы клинической фармакологии противоаритмических средств. Моисеева И.Я - 73 стр.

UptoLike

ВУЗ: 

ПГУ | Пенза

Составители: 

Рубрика: 

75
55. Sim I., McDonald K., Lavori P. Quantitative overview or randovized trials
amiodarone to prevent sudden cardiac death. Circulanion, 1997, 86,(9), 2823-
2829.
56. Pagano L., Della Monica R., Malinconico M. Proarrhythmia due to the
amiodarone. Minervf\a Cardioangiol. 2001; 49 (6): 421-428.
57. Task Ferport. ACC/AHA/ESC guidelines for the management of patients with
atrial fibrillation. Europ Heart J.,2001,22,1852-1923.
58. Tamargo J. Drug-induced torsade de pointes: from molecular biology to
bedside. Jpn J Pharmacol 2000; 83: 1-19.
59. The Atrial Fibrillation Follow-up Investigation of Rhythm Management
(AFFIRM ) Investigators. A comharison of rate control and rhythm control in
patients with atrial fibrillation. N. Engl. J. Med., 2002,347 (23), 1825-1833.
60. The Sicilian Gambit. // Europ.Heart.J. - 1991.- Vol.12.- P.1112-1131.
61. The UK Propafenone PSVT Study Group. A randomized, placebo-controlled
trial of propafenone in the prophylaxis of paroxysmal supraventricular
tachycardia fnd hfroxysmal atrial fibrillation. Circulation, 1995, 92, 2550-
2557.
62. Van Gelder I., Hagens V., Bosker H. Et al. A comparison of ratecontrol and
rtythm control in patints with recurrent persistent atrial fibrillation. N. Engl/ J
Med., 2002,347 (23), 1834-1840.
63. Viskin S., Fish R. Prevention of ventricular arrhythmias in the congenital long
QT Cardiol Rep 2000; 2: 492-497.
64. Viskin S., Belhassen B. // Amer.Heart.J.- 1990.- Vol.1.- P.180-188.
65. Viskin S. Current treatment options in cardiovascular medicine 1999; 187-195.
66. Vaughan-Williams E.M. Classifying Antiarrhythmic actions: by Facts or
Speculation. // J.Clin.Pharmacol.- 1992.- Vol.32.- P.964-977.
67. Witchel H.J., Hancox J.C. Familial and acquired lond QT syndrome and the
cardiac rapid delayed rectifier potassium current. Clin Exp. Pharmacol
Phusiol 2000; 27: 753-766. 
55. Sim I., McDonald K., Lavori P. Quantitative overview or randovized trials
      amiodarone to prevent sudden cardiac death. Circulanion, 1997, 86,(9), 2823-
      2829.
56.   Pagano L., Della Monica R., Malinconico M. Proarrhythmia due to the
      amiodarone. Minervf\a Cardioangiol. 2001; 49 (6): 421-428.
57. Task Ferport. ACC/AHA/ESC guidelines for the management of patients with
      atrial fibrillation. Europ Heart J.,2001,22,1852-1923.
58.   Tamargo J. Drug-induced torsade de pointes: from molecular biology to
      bedside. Jpn J Pharmacol 2000; 83: 1-19.
59. The Atrial Fibrillation Follow-up Investigation of Rhythm Management
      (AFFIRM ) Investigators. A comharison of rate control and rhythm control in
      patients with atrial fibrillation. N. Engl. J. Med., 2002,347 (23), 1825-1833.
60. The Sicilian Gambit. // Europ.Heart.J. - 1991.- Vol.12.- P.1112-1131.
61. The UK Propafenone PSVT Study Group. A randomized, placebo-controlled
      trial of propafenone in the prophylaxis of paroxysmal supraventricular
      tachycardia fnd hfroxysmal atrial fibrillation. Circulation, 1995, 92, 2550-
      2557.
62. Van Gelder I., Hagens V., Bosker H. Et al. A comparison of ratecontrol and
      rtythm control in patints with recurrent persistent atrial fibrillation. N. Engl/ J
      Med., 2002,347 (23), 1834-1840.
63. Viskin S., Fish R. Prevention of ventricular arrhythmias in the congenital long
      QT Cardiol Rep 2000; 2: 492-497.
64. Viskin S., Belhassen B. // Amer.Heart.J.- 1990.- Vol.1.- P.180-188.
65. Viskin S. Current treatment options in cardiovascular medicine 1999; 187-195.
66. Vaughan-Williams E.M. Classifying Antiarrhythmic actions: by Facts or
      Speculation. // J.Clin.Pharmacol.- 1992.- Vol.32.- P.964-977.
67. Witchel H.J., Hancox J.C. Familial and acquired lond QT syndrome and the
      cardiac rapid delayed rectifier potassium current. Clin Exp. Pharmacol
      Phusiol 2000; 27: 753-766.



                                           75

Страницы